GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions,
What's Next for Alzheimer's Treatment? Some Scientists Are Betting on GLP-1 Drugs
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
GLP-1 weight-loss drugs may cut risk of dementia and other conditions
GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and dementia.
Benefits and risks of GLP-1 drugs and criteria for dementia diagnosis
In today’s health headlines, the 175 health benefits and risks of taking GLP-1 drugs. Also, many older adults don’t realize they meet the criteria for a dementia diagnosis. Finally, what are the brain effects of short video watching on TikTok and reels?
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
A woman regained weight after she stopped taking semaglutide. Now she works 2 jobs to afford it.
A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...
BioPharma Dive6d
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
TCTMD2d
European Medicines Agency Investigating GLP-1 Drugs and Eye Disease
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
News Medical on MSN3d
Researchers create an atlas of health associations for GLP-1 receptor agonists
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
HealthDay on MSN1d
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...